iShares Core MSCI Emerging Markets ETF vs Liquidia Corporation Common Stock — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $76.95 (market cap $158.70B), while Liquidia Corporation Common Stock trades at $34.26 (market cap $2.40B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 66.1× Liquidia Corporation Common Stock's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 59 Days and Liquidia Corporation Common Stock for 0 Days on average.
| IEMG | LQDA | |
|---|---|---|
Market Cap | $158.70B | $2.40B |
Volume | 9,865,871 | 2,857,547 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $91.03 |
52-Week Low | $64.72 | $22.02 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $2.30B |
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $80.22, down 0.51% with a bearish technical signal from moving averages. The ETF faces neutral oscillators but shows support at $79-80 levels. Recent news highlights IEMG's strong performance against peers like SCHE and VWO, with emerging markets attracting record inflows amid dollar weakness and tech sector exposure.
Outlook remains mixed: technical weakness contrasts with fundamental appeal via low-cost emerging market access and 35% trailing returns. Risks include concentration in tech, volatility, and expense ratio disadvantages versus competitors. Analyst sentiment leans cautious due to recent underperformance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →